GLP-1 combo helps patients with diabetes lose 23% bodyweight
A combination of two weight-loss drugs led to a 23 percent reduction in body weight among people with obesity and type 2 diabetes in under a year. That is substantially more than either drug achieved on its own.
Pharmaceutical company Eli Lilly tested its GLP-1 drug Zepbound alongside eloralintide, a candidate drug that targets amylin. Amylin is a hormone produced by the pancreas that helps regulate appetite and blood sugar levels. Zepbound works via a different hormone, GLP-1, which also suppresses appetite and stimulates insulin production.
In a mid-stage clinical trial, participants with obesity and type 2 diabetes received different combinations of the two drugs. The researchers presented the results at the annual meeting of the European Association for the Study of Diabetes. After 48 weeks, the group on the highest dose of the combination had lost an average of 23.3 percent of their body weight.
More than the sum of its parts
For comparison: participants taking Zepbound alone lost 14.8 percent, and those on the highest dose of eloralintide alone lost 11.1 percent. The combination outperformed both individual treatments. That is notable because people with diabetes typically respond less strongly to weight-loss medications than those without the condition.
There is, however, a caveat. A high proportion of participants stopped treatment early. This raises questions about tolerability: side effects, likely nausea and gastrointestinal complaints common with GLP-1 agents and amylin analogues, may be responsible. Full data on dropout rates and side effects have not yet been published.
Why this matters for aging
Obesity and related metabolic disorders are among the strongest risk factors for accelerated biological aging. Adipose tissue, particularly the kind that accumulates around organs, promotes chronic inflammation and insulin resistance. From a longevity perspective, a safe and effective drug that amplifies weight loss is therefore of interest, though this study did not examine long-term effects on aging, and the research is still at an early stage.
Eli Lilly is in a race with other pharmaceutical companies to bring next-generation weight-loss drugs to market. These results are encouraging, but questions about safety and tolerability over the long term remain unanswered for now.
Search terms for further research: GLP-1 amylin combination therapy, tirzepatide weight loss diabetes, obesity pharmacotherapy metabolic aging